OncoMatch/Clinical Trials/NCT07205536

Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy

Official title: A Clinical Study on the Safety and Efficacy of Mecapegfilgrastim in Preventing Myelosuppression Induced by Concurrent Chemoradiotherapy for Thoracic Malignancies

Is NCT07205536 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including Mecapegfilgrastim and Oral or short-acting granulocyte-stimulating agents for myelosuppression.

Treatment: Mecapegfilgrastim · Oral or short-acting granulocyte-stimulating agents — This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.